Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.40 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136207 | 0.94 | USP30 (0.42) | USP30KDM2BSLC9A3CYP2D6SLC18A3 | |
| SCHEMBL4141043 | 0.91 | KDM2B (0.38) | USP30KDM2BDRD3CYP11B2 | |
| SCHEMBL4128738 | 0.90 | USP30 (0.36) | USP30KDM2BAKR1C3DRD3CYP11B2 | |
| SCHEMBL4142661 | 0.88 | USP30 (0.43) | USP30SLC9A3CYP2D6DRD3CYP11B2 | |
| SCHEMBL4140902 | 0.88 | USP30 (0.43) | USP30SLC9A3CYP2D6DRD3CYP11B2 | |
| SCHEMBL4140906 | 0.88 | USP30 (0.43) | USP30SLC9A3CYP2D6DRD3CYP11B2 | |
| SCHEMBL4144821 | 0.88 | USP30 (0.43) | USP30CYP2D6DRD3CYP11B2JAK2 | |
| SCHEMBL4139871 | 0.87 | USP30 (0.43) | USP30SLC9A3CYP2D6DRD3JAK2 | |
| SCHEMBL4136604 | 0.82 | KDM2B (0.42) | USP30KDM2BDRD3CYP11B2 | |
| SCHEMBL4136683 | 0.80 | JAK3 (0.51) | USP30KDM2BAKR1C3DRD3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | USP30 3191/4885KDM2B 3965/4885SLC9A3 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.